8-K: Exicure Receives Nasdaq Delinquency Notice for Late Quarterly Report Filing

Exicure, Inc. announced it received a delinquency notification from Nasdaq due to its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.

Summary

• Exicure, Inc. (Nasdaq: XCUR) received a delinquency notification letter from The Nasdaq Stock Market LLC on May 21, 2025.
• The company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all periodic financial reports with the SEC, due to the delayed filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.
• Exicure has 60 calendar days from the notice date to submit a plan to Nasdaq detailing how it intends to regain compliance.
• If Nasdaq accepts the plan, the company may be granted an extension of up to 180 calendar days from the original Form 10-Q due date, or until November 17, 2025, to regain and maintain compliance.
• Company management is actively working to complete and file the Form 10-Q as soon as practicable to resolve the non-compliance.
• A press release announcing the receipt of the Nasdaq letter was issued on May 28, 2025.

Sentiment

Score: 3

Explanation: The document indicates a significant compliance issue with Nasdaq due to a late financial filing, which is a negative event. While management states they are working to resolve it, the immediate impact is negative. The mention of potential equity investment is a positive for liquidity but also suggests a need for capital, which could be dilutive.

Positives

• Management has stated they are working diligently to complete and file the Form 10-Q as soon as practicable to regain compliance.

Negatives

• Receipt of a delinquency notification from Nasdaq for non-compliance with a fundamental listing rule.
• Failure to timely file the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, by its May 20, 2025, due date.
• The company faces the risk of delisting from Nasdaq if it fails to regain compliance within the stipulated timeframe.

Risks

• Potential delisting from The Nasdaq Stock Market LLC if Exicure fails to regain compliance with Nasdaq Listing Rule 5250(c)(1) by filing its Form 10-Q within the specified deadlines.
• Reputational damage and potential loss of investor confidence due to non-compliance with regulatory filing requirements.
• The company has a limited timeframe (60 days to submit a plan, and potentially until November 17, 2025) to resolve the filing delinquency and avoid further enforcement actions from Nasdaq.

Future Outlook

The company is pursuing strategic alternatives to maximize stockholder value, and is anticipating the timing of an equity investment closing and potential additional equity investment. The company also anticipates the Nasdaq Hearings Panel process and potential results related to its compliance status.

Management Comments

• "The Companys management is working diligently to complete the Form 10-Q and intends to file the Form 10-Q as soon as practicable to regain compliance with Nasdaq Listing Rule 5250(c)." Andy Yoo, Chief Executive Officer.

Industry Context

This announcement is specific to Exicure's compliance with Nasdaq listing rules and does not directly reflect broader industry trends. However, timely financial reporting is a fundamental expectation across all publicly traded companies in the biotechnology sector and beyond, ensuring transparency and investor confidence.

Stakeholder Impact

• Shareholders: Face increased risk of delisting, potential negative impact on share price, and reduced transparency due to delayed financial information.
• Regulatory Authorities: Nasdaq has issued a formal notice of non-compliance, requiring a plan of action and adherence to strict deadlines.
• Management: Under significant pressure to complete and file the Form 10-Q promptly and regain compliance to avoid further penalties or delisting.

Next Steps

• Exicure must submit a plan to Nasdaq within 60 calendar days to address how it intends to regain compliance.
• Exicure intends to file the Form 10-Q as soon as practicable to regain compliance.
• The company may engage in the Nasdaq Hearings Panel process if its plan is not accepted or if it fails to regain compliance within the extended period.

Key Dates

Recommendation

Keywords

Exicure, XCUR, Nasdaq, delinquency notice, Form 10-Q, late filing, compliance, listing rules, biotechnology, clinical-stage, hematologic diseases, GPC-100